Cagrilintide 5mg

▎ Kūlana Cagrilintide

▎ Noiʻi Cagrilintide

He aha ke kumu o Cagrilintide?

ʻO Cagrilintide—he mea hoʻohālikelike amylin:

ʻO Amylin kahi hormone i huna ʻia e ka pancreatic islet β cell. Ma lalo o nā kūlana physiological, hui pū ʻo ia me ka insulin a loaʻa i ka nui o nā hana physiological koʻikoʻi.

ʻO ka mea mua, he hana koʻikoʻi ka amylin i ka hoʻoulu ʻana i ka satiety a me ka hōʻemi ʻana i ka ʻai. ʻO kāna hana o ka hana e pili ana i ka hoʻoulu ʻana i nā mea loaʻa i ka Area Postrema ma ke kumu o ka ventricle ʻehā. Hoʻouna ʻia nā hōʻailona neural i ka forebrain ma o ka Nucleus of the Solitary Tract. I ka manawa like, hiki ke lawe ʻia i ka Lateral Hypothalamic Area a me nā hui nuklea hypothalamic ʻē aʻe ma o ka Lateral Parabrachial Nucleus. Hiki iā Amylin ke hoʻoulu i ke kikowaena satiety o ke kino a keʻakeʻa i ka ʻai ʻana i nā holoholona ^[1].

Hiki iā Amylin ke hoʻoponopono i ka homeostasis glucose, i loaʻa ma ke kāohi ʻana i ka huna ʻana o ka insulin a me ka glucagon ^[2] . Hāʻawi nui kēia hana i ka mālama ʻana i ke kūpaʻa o nā pae glucose koko a paʻa i ka mea nui no ka mālama ʻana i nā maʻi e like me ka maʻi diabetes.

Eia kekahi, hoʻohana ka amylin i kona hopena ma ka hoʻoulu ʻana i ka hoʻokuʻu ʻana o nā neurotransmitters. No ka laʻana, ke kāohi nei ia i ka hoʻokuʻu ʻana o ka dopamine i ka hypothalamus o nā ʻiole, ʻoiai he hopena liʻiliʻi i ka norepinephrine a me ke serotonin ^[3] . I loko o ka pōʻaiapili o ka homeostasis glucose, mālama ka amylin i ka paʻa o ka glucose koko ma ke kāohi ʻana i ka huna ʻana o ka insulin a me ka glucagon. ʻO kāna mau hana e hana pololei ana i nā ʻāpana pancreatic islet α a me ka hoʻoponopono ʻole ʻana i ka huna ʻana o ka glucagon ma o ka neural signal transduction i ka hypothalamus. I ka poʻe maʻi me ka maʻi maʻi, ʻo ka luku ʻana i nā cell β ʻaʻole i alakaʻi wale i ka hemahema o ka insulin akā ua hopena pū kekahi i ka emi ʻana o ka huna ʻana o C-peptide a me amylin. Ua ʻike ʻia ʻo Amylin i ka hoʻoponopono ʻana i ka homeostasis glucose ma ke kāohi ʻana i ka hoʻokaʻawale ʻana o ka ʻōpū a me ka hana ʻana o ka glucose hepatic postprandial, i ka hopena e hōʻemi ana i ka fluctuations koko postprandial ^[4] . Eia hou, hiki i ka amylin ke hoʻopaneʻe i ka hoʻokuʻu ʻana o ka ʻōpū, kaohi ʻana i ka peristalsis o ka ʻōpū ma o ka ʻōnaehana nūnū waena, a hoʻolōʻihi i ka manawa noho o ka meaʻai i loko o ka ʻōpū o ka ʻōpū, e pale ai i ka piʻi wikiwiki ʻana o ka glucose koko.

Eia nō naʻe, he pōkole ka hapalua o ke ola o ka amylin, kahi e kaupalena ai i kāna noi lapaʻau. Hōʻike ka noiʻi ʻo ka amylin analog, pramlintide, ma ke ʻano he lāʻau adjuvant no ka mālama ʻana i ka maʻi maʻi diabetes, pono e hoʻokele ʻekolu manawa i ka lā. ʻAʻole kēia e hoʻopilikia wale i nā poʻe maʻi akā e hōʻemi hoʻi i kā lākou hoʻokō ^[5] . No ka hoʻoponopono ʻana i ka pilikia o ka hapalua ola pōkole o ka amylin maoli, ua hoʻomohala ʻia ʻo Cagrilintide ma ke ʻano he analog lōʻihi. Hoʻokumu ʻia ka hoʻomohala ʻana o Cagrilintide i kahi ʻike hohonu o nā hana physiological o ka amylin maoli. Manaʻo ia e hoʻohālikelike i ka hana o ka amylin i ka wā e hoʻonui ai i ka paʻa a me nā waiwai lōʻihi o ka lāʻau lapaʻau e hoʻokō i nā koi o ka mālama lapaʻau.

ʻO nā pono kūpono a me ka Pharmacological o Cagrilintide

ʻO Cagrilintide kahi mea hoʻohālikelike amylin lōʻihi me ka mana nui, e hōʻike ana i nā hopena kupaianaha i ka mālama ʻana i ka momona a me ka maʻi diabetes. Lipidated a loaʻa nā ʻano hana lōʻihi paʻa ^[5] . ʻO Amylin kahi hormone i hoʻokuʻu pū ʻia e nā pancreatic β cell me ka insulin, kahi e hoʻoulu ai i ka satiety ma ka hana ʻana i nā ʻāpana homeostatic a hedonic o ka lolo. Ma ke ʻano he analogue o ka amylin, hiki iā Cagrilintide ke hoʻohālike i kēia hopena, e hoʻoulu ai i ka satiety a pēlā e kōkua ai i ka mālama kaumaha. Eia kekahi, ʻo Cagrilintide he amylin ʻelua a me ka calcitonin receptor agonist, i loaʻa mai ka iwi kuamoʻo amylin, e hāʻawi iā ia me kahi hana kūʻokoʻa o ka hana i ka hoʻoponopono metabolic.

ʻO ka holomua o nā haʻawina lāʻau lapaʻau ma Cagrilintide

I nā hoʻokolohua lapaʻau, ua hāʻawi ʻo Cagrilintide i nā hopena hoʻohiki i ka hoʻoiho ʻana i ke kaumaha. No ka laʻana, i loko o kahi multicenter, randomized, double-blind, placebo-controlled, and active-controlled phase 2 dose-fining trial, nā poʻe i mālama ʻia me Cagrilintide ua hōʻike ʻoi aku ka nui o ka pohō kaumaha ma mua o ka poʻe e loaʻa ana i ka placebo. ʻOi aku ka kiʻekiʻe (6.0% - 10.8%) ma mua o ka hui placebo (3.0%) ka hapa pākēneka o ka hoʻemi ʻana i ke kaumaha mai ka papa kuhikuhi no nā kumu a pau o Cagrilintide (0.3 - 4.5 mg). ʻOi aku ka nui o ka emi ʻana o ke kaumaha ma ka hui i mālama ʻia me 4.5 mg o Cagrilintide ma mua o ka hui i mālama ʻia me 3.0 mg o liraglutide (10.8% vs. 9.0%). Hōʻike kēia mau hopena e hiki ke lilo ʻo Cagrilintide i koho kūpono no ka hoʻokele paona ^[6].

ʻO Cagrilintide a me ka GLP-1 receptor agonist semaglutide loaʻa nā ʻano hana like ʻole o ka hana. Hoʻohana ʻo Semaglutid i kāna mau hopena ma ka hana ʻana i nā mea loaʻa GLP-1 i ka hypothalamus, e alakaʻi ana i ka emi ʻana o ka makemake, ka hoʻonui ʻana i ka huna ʻana o ka insulin, a me ka lohi i ka hoʻokuʻu ʻana o ka ʻōpū. ʻO ka mea ʻē aʻe, hoʻopau hou ʻo Cagrilintide i ka ʻai ma ka hoʻoulu ʻana i nā mea hoʻokipa amylin. ʻO ka hui pūʻana o kēia mau mea hanaʻelua e hoʻonui i ka hopena ma luna o ka makemake ma o nā mīkini he nui, e hoʻonui nui i ka pono o ke kaumaha ^[7] . Hāʻawi ʻia i ke ʻano paʻakikī o ka momona, ʻo ka hui ʻana o ka lāʻau lapaʻau e ʻimi ana i nā hopena pathophysiological he mea hoʻolālā kūpono a maikaʻi.

Eia kekahi, ua hōʻike pū ʻo Cagrilintide i ka hiki ke hoʻomalu i ka glucose koko i nā mea maʻi me ka maʻi diabetes type 2. Ua hōʻike ʻia nā noiʻi maʻi e hōʻike ana ʻo Cagrilintide i ke kūpaʻa maikaʻi a me ka maikaʻi i ka mālama ʻana i ka momona a me ka maʻi diabetes type 2. No ka laʻana, i loko o kahi hoʻokolohua lapaʻau e pili ana i nā poʻe maʻi me ka maʻi diabetes type 2, ʻo ka hui pū ʻana o Cagrilintide a me ka GLP-1 receptor agonist semaglutide i hōʻike i ka mana o ka glucose koko a me nā hopena hoʻemi kaumaha. Hōʻike kēia i ka mālama ʻana o Cagrilintide i kahi kiʻekiʻe o ke kūpaʻa i ka hoʻomaʻamaʻa lapaʻau a hiki iā ia ke hana i nā hopena therapeutic mau. Ma kahi hoʻokolohua lapaʻau ʻē aʻe, ʻo Cagrilintide, inā i lawelawe wale ʻia a i hui pū ʻia me ka semaglutide, hōʻike i ka hoʻomanawanui maikaʻi a me ka palekana ^[8] . Ke hōʻoia hou nei kēia i ka paʻa o Cagrilintide, e like me nā noi lapaʻau, pili ka paʻa o kahi lāʻau me kona ʻae a me ka palekana.

ʻO ka mea hope loa, i nā hoʻokolohua lapaʻau, ua ʻae maikaʻi ʻia ka mālama ʻana me ka cagrilintide. I ka pae 2 hoʻāʻo ʻimi noiʻi, ua hoʻohālikelike ʻia nā helu o ka hoʻopau ʻana i ka mālama mau ma waena o nā hui lapaʻau like ʻole, ka mea nui i pili i nā hanana ʻino. Eia nō naʻe, ʻo nā maʻi ʻino i hoʻolaha nui ʻia ʻo ia nā maʻi ʻōpū a me nā hopena o ka wahi i hoʻopaʻa ʻia, me ka hapa nui o ka maʻi a me ka haʻahaʻa. Ma kahi ho'āʻo 1b i hoʻopaʻa ʻia, ʻo ka mālama like ʻana me ka cagrilintide a me 2.4 mg o semaglutide i hōʻike pū i ka hoʻomanawanui maikaʻi a me kahi ʻōlelo palekana palekana ^[9]. Pono nā hoʻokolohua ʻoi aku ka nui a me ka lōʻihi i ka wā e hiki mai ana no ka loiloi piha ʻana i ka maikaʻi a me ka palekana o kēia lāʻau hoʻohui.

Ke Ana Hoʻohālike o Cagrinlintide

Puna:PubMed ^[5]

ʻO ke koʻikoʻi o ka hoʻohana ʻana iā Cagrilintide

ʻO ka puka ʻana o Cagrilintide ua lawe mai i ka manaʻolana hou i ka mālama ʻana i ka momona a me ka maʻi diabetes type 2. ʻOiai ka piʻi nui ʻana o ka pilikia o ka nui o ka honua, ʻo nā koho i ʻae ʻia i kēia manawa no ka lāʻau lapaʻau e kaupalena ʻia. Ma ke ʻano he analogue amylin lōʻihi, hāʻawi ʻo Cagrilintide i kahi koho therapeutic hou no nā poʻe maʻi obese, ʻoi aku ka poʻe i pane maikaʻi ʻole i ka hana ʻana i ke ola a ʻaʻole kūpono no ka hana bariatric. Loaʻa iā ia ka hoʻokele paona ma o ka hana ʻokoʻa o ka hana, hāʻawi i nā manaʻo hou a me nā ʻano hana no ka mālama ʻana i ka momona, a hiki ke hōʻike i ka maikaʻi a me ka palekana i hoʻohālikelike ʻia me nā lāʻau anti-obesity kahiko ^[7] . Eia kekahi, ʻo ka hihia kūleʻa o ka hui pū ʻana o Cagrilintide a me semaglutide (CagriSema) e hōʻike ana i ka hui ʻana o ka hui ʻana i nā pahuhopu pathophysiological he hoʻolālā kūpono no ka hoʻonui ʻana i ka pane ʻana i ka lāʻau i ka momona ^[8] . ʻAʻole hāʻawi kēia ʻano lapaʻau multi-target i kahi paradigm hou no ka mālama ʻana i ka momona akā lawe pū kekahi i nā hoʻomaikaʻi metabolic koʻikoʻi i nā poʻe maʻi me ka maʻi diabetes type 2.

I ka hopena, ma ke ʻano he analogue amylin lōʻihi, ʻo Cagrilintide ka mana kupaianaha no ka pohō kaumaha a me ka hoʻokele glucose koko. Hoʻola ia i ke ala hōʻailona maʻaʻa ma ka hoʻohālikelike ʻana i ka hana a amylin a hoʻoponopono i ka metabolism ma ke ʻano he agonist ʻelua. Ua hōʻike ʻia nā hoʻokolohua lapaʻau ʻo Cagrilintide, i hoʻohana wale ʻia a i hui pū ʻia me ka semaglutide, hiki ke hōʻemi nui i ke kaumaha o ke kino a ua ʻae maikaʻi ʻia. Eia kekahi, ua hōʻike pū ia i ka hiki ke hoʻomalu i ka glucose koko i nā poʻe maʻi me ka maʻi diabetes type 2, e hāʻawi ana i kahi koho hou no ka mālama ʻana i ka momona a me ka maʻi diabetes a me ka hoʻopiha ʻana i ke āpau i nā regimens lapaʻau e kū nei, ʻoi aku hoʻi no kēlā poʻe maʻi me nā pane maikaʻi ʻole i ka hana ʻana i ka nohona a ʻaʻole kūpono no ka ʻoki. Hāʻawi kāna hoʻolālā lapaʻau multi-target i nā ʻike hou no ka mālama ʻana i nā maʻi metabolic.

No ka mea kakau

ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.

Mea kākau moʻolelo ʻepekema

He kaukaʻi ʻo Kauka DCW Lau ma ke kula ʻo Cumming School of Medicine, University of Calgary, Canada. ʻO kāna mau noiʻi noiʻi e pili ana i ka endocrinology a me ka metabolism, ka lāʻau lapaʻau maʻamau a me loko, ka ʻōnaehana cardiovascular a me ka cardiology, ke olakino lehulehu, ke olakino a me ka ʻoihana, a me ka oncology. Loaʻa iā ia nā kūlana me Alberta Health Services (AHS) a me Obesity Canada a hana ʻo ia ma ka Julia McFarlane Diabetes Research Center. He ʻike nui ʻo Dr. Lau ma nā ʻano o ka maʻi maʻi a me ka noiʻi ʻana i ka momona, me kāna hana i paʻi ʻia ma nā puke moʻolelo hoʻonaʻauao e like me ka Canadian Journal of Diabetes. Ua helu ʻia ʻo Kauka DCW ma ka ʻōlelo kuhikuhi [6].

▎ Nā ʻōlelo pili

[1] Hansen KE, Murali S, Chaves IZ, Suen G, Ney DM. Hoʻopilikia ʻo Glycomacropeptide i ka Amylin-Mediated Satiety, Postprandial Markers of Glucose Homeostasis, a me ka Fecal Microbiome i Obese Postmenopausal Women. J NUTR 2023; 153(7): 1915-29. DOI:10.1016/j.tjnut.2023.03.014.

[2] Ling W, Huang Y, Qiao Y, Zhang X, Zhao H. Human Amylin: Mai ka Pathology a Physiology a me Pharmacology. CURR PROTEIN PEPT SC 2019; 20(9): 944-57. DOI:10.2174/ 13892037206 66 19032811183 3.

[3] Brunetti L, Recinella L, Orlando G, Michelotto B, Di Nisio C, Vacca M. Nā hopena o ka ghrelin a me ka amylin ma ka dopamine, norepinephrine a me ka hoʻokuʻu serotonin i ka hypothalamus. EUR J PHARMACOL 2002; 454(2-3): 189-92. DOI:10.1016/S0014-2999(02)02552-9.

[4] Gedulin BR, Jodka CM, Herrmann K, Young AA. ʻO ke kuleana o ka amylin endogenous i ka huna ʻana o ka glucagon a me ka hoʻokaʻawale ʻana o ka ʻōpū i nā ʻiole i hōʻike ʻia me ka antagonist koho, AC187. Nā Peptides Hoʻoponopono 2006; 137(3): 121-7. DOI:10.1016/j.regpep.2006.06.004.

[5] Kruse T, Hansen JL, Dahl K, et al. Ka hoʻomohala ʻana o Cagrilintide, kahi Amylin Analogue lōʻihi. J MED CHEM 2021; 64(15): 11183-94. DOI:10.1021/acs.jmedchem.1c00565.

[6] Lau DCW, Erichsen L, Francisco AM, et al. ʻO ka cagrilintide hoʻokahi pule no ka hoʻokele paona i nā poʻe me ke kaumaha a me ka momona: kahi multicentre, randomized, double-blind, placebo-controlled and active-controlled, dose-fining phase 2 ho'āʻo. LANCET 2021; 398(10317): 2160-72. DOI:10.1016/S0140-6736(21)01751-7.

[7] D'Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: He Amylin Analog lōʻihi no ka mālama ʻana i ka momona. CARDIOL REV 2024; 32(1): 83-90. DOI:10.1097/CRD.0000000000000513.

[8] Frias JP, Deenadayalan S, Erichsen L, et al. ʻO ka maikaʻi a me ka palekana o ka cagrilintide 2.4 mg i hoʻokahi pule i hoʻokahi pule me ka semaglutide 2.4 mg i hoʻokahi pule i ka maʻi diabetes type 2: kahi multicentre, randomised, double-blind, active-controlled, phase 2 trial. LANCET 2023; 402(10403): 720-30. DOI:10.1016/S0140-6736(23)01163-7.

[9] Enebo LB, Berthelsen KK, Kankam M, et al. Ka palekana, ka hoʻomanawanui, ka pharmacokinetics, a me ka pharmacodynamics o ka hoʻokele like ʻana o ka nui o ka cagrilintide me ka semaglutide 2.4 mg no ka hoʻokele paona: kahi randomised, controlled, phase 1b trial. LANCET 2021; 397(10286): 1736-48. DOI:10.1016/S0140-6736(21)00845-X.

ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.  

ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a i ʻole maʻi. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.